Bristol Myers Teams Up With Microsoft to Use AI for Early Lung Cancer Detection
GeokHub
New York | Jan 20, 2026 Pharmaceutical giant Bristol Myers Squibb has entered a partnership with Microsoft to deploy artificial intelligence–powered imaging tools aimed at improving the early detection of lung cancer, the companies announced on Tuesday.
Under the agreement, Bristol Myers will leverage FDA-cleared radiology AI algorithms delivered through Microsoft’s Precision Imaging Network, a platform used by U.S. hospitals to analyze X-ray and CT scans for signs of lung disease.
Improving Early Diagnosis
The AI system is designed to assist clinicians in identifying subtle lung nodules that are often difficult to detect in early-stage disease. Bristol Myers said earlier identification could help guide patients to timely care and more targeted treatment options, particularly for non-small cell lung cancer, the most common form of the disease.
The companies said the technology is already in use across parts of the U.S. healthcare system and is intended to integrate seamlessly into existing clinical workflows.
Focus on Underserved Communities
A central goal of the collaboration is expanding access to early lung cancer screening in medically underserved areas, including rural hospitals and community clinics that may lack specialized diagnostic resources.
“By combining Microsoft’s scalable imaging technology with our oncology expertise, we aim to support clinicians in identifying patients sooner and connecting them with the most appropriate precision therapies,” said Alexandra Goncalves, Vice President and Head of Digital Health at Bristol Myers Squibb.
AI’s Growing Role in Drug Development
The partnership reflects a broader trend across the pharmaceutical industry, where companies are increasingly adopting artificial intelligence to enhance research, diagnostics, and patient care.
AI tools are being used not only to support early disease detection but also to streamline drug discovery and development. Last week, AstraZeneca announced an acquisition of AI-focused oncology startup Modella AI, underscoring growing investment in data-driven cancer research.
